LTP·01learntopeptide
Healing & repairEvidence C4 cited

RGTA OTR4120

aka RGTA · OTR4120 · OTR4131 · ReGeneraTing Agent · heparan sulfate mimetic · matrix therapy

RGTA OTR4120 is a synthetic heparan sulfate mimetic designed to protect and stabilise endogenous growth factors within the extracellular matrix (ECM) at sites of tissue injury. Developed through research on glycosaminoglycan analogues, OTR4120 replaces damaged heparan sulfate proteoglycans destroyed during tissue injury by enzymatic degradation. By binding to heparan sulfate binding sites on matrix proteins and growth factors such as FGF, VEGF, TGF-beta, and HGF, OTR4120 shields these signalling molecules from proteolytic degradation, preserving their bioactivity and spatial organisation. This allows the natural wound healing cascade to proceed more efficiently, accelerating tissue regeneration in chronic wounds, burns, corneal injuries, and musculoskeletal damage.

Sequence

Read this before quoting the sequence
Not a peptide. RGTA (ReGeneraTing Agent) OTR4120 is a synthetic polysaccharide: a dextran backbone chemically substituted with carboxymethyl and sulfate groups, described in the primary literature as 'alpha1-6 polycarboxylmethylsulfate glucose'. It is engineered as a heparan sulfate mimetic; because its subunits are joined by alpha1-6 linkages it resists degradation by endoglycosidases. No amino acid sequence exists.
Source ↗

Mechanism of action

OTR4120 functions as a heparan sulfate mimetic, replacing endogenous heparan sulfate proteoglycans destroyed at injury sites by glycanases released during inflammation. Heparan sulfates normally serve as a scaffold within the ECM, binding and protecting growth factors essential for tissue repair. When these proteoglycans are degraded, growth factors become vulnerable to proteolysis and lose their spatial organisation. OTR4120 binds to the same sites on matrix proteins, reconstituting the protective microenvironment and preserving growth factor bioavailability and signalling gradients.

What the evidence actually shows

Grade C

Evidence for OTR4120 is primarily derived from animal studies and limited clinical observations. Preclinical studies in various wound healing models demonstrate accelerated tissue repair and improved growth factor retention. Small clinical case series report positive outcomes in chronic wound healing, corneal ulcer repair, and muscle injury recovery. Large-scale randomised controlled trials in humans are lacking.

Regulatory status

Status
No FDA or EMA marketing authorisation as a medicinal product was identified. The primary literature states OTR4120 is 'already used in clinics in two commercially available products', one for chronic skin lesions and one for corneal lesions, but does not state their regulatory classification.
Source ↗

Dosing — what backs each figure

OTR4120 is the heparan-sulfate mimetic in CACIPLIQ20, a CE-marked class III medical device rather than an FDA- or EMA-approved drug; the documented human use is topical application to the wound bed twice weekly for up to 12 weeks, supported by a small randomized controlled trial in diabetic foot ulcers and several case series. It is a wound dressing regimen, not a systemic dose.

ClinicalApproved labelling or a published human trial
PreclinicalAnimal studies — not a human dose

  • Topical RGTA OTR4120 matrix therapy applied to deep second-degree burns (dose/schedule not stated in abstract)

    hairless rat · topical · PMID 21285759

Animal doses do not convert to human doses by body weight alone. Route matters too — a compound dosed intraperitoneally in mice tells you little about subcutaneous use.

Handling and storage

No compound-specific stability data exists
No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. OTR4120 is a polymer supplied in commercial topical/ophthalmic presentations; no storage specification from a regulatory document was located. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

References (4)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
molecularFormula, molecularWeight, casNumber, pubchemCid, storage, reconstitution, regulatory.status, regulatory.wada, regulatory.clinicalStage

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Healing & repair

BPC-157
A synthetic pentadecapeptide derived from a protein found in gastric juice. Studied for tissue repair, tendon/ligament healing, and gut protection in preclinical models.
BPC-157 Arginate
BPC-157 Arginate is the arginine salt form of Body Protection Compound 157, a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. This formulation pairs the BPC-157 peptide with arginine as a counter-ion, which proponents claim provides improved stability and enhanced oral bioavailability compared to the standard acetate salt form. The underlying peptide consists of 15 amino acids and has demonstrated cytoprotective, anti-inflammatory, and tissue-healing properties across numerous preclinical studies. It promotes angiogenesis, modulates nitric oxide pathways, and upregulates growth factor expression. The arginate form is marketed as offering better gastric survival and systemic absorption when taken orally, though direct head-to-head comparative data remains limited.
GV1001
A 16-amino acid peptide derived from the active site of human telomerase reverse transcriptase (hTERT). Originally developed as a cancer immunotherapy vaccine, now investigated for anti-inflammatory and anti-aging properties.